Mateon enters into merger agreement with PointR Data to leverage disruptive AI technology
Mateon Therapeutics and PointR Data announced a merger agreement creating a publicly traded artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. August 19, 2019